417 related articles for article (PubMed ID: 35383826)
21. The accuracy and robustness of plasma biomarker models for amyloid PET positivity.
Benedet AL; Brum WS; Hansson O; ; Karikari TK; Zimmer ER; Zetterberg H; Blennow K; Ashton NJ
Alzheimers Res Ther; 2022 Feb; 14(1):26. PubMed ID: 35130933
[TBL] [Abstract][Full Text] [Related]
22. Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative.
Zettergren A; Lord J; Ashton NJ; Benedet AL; Karikari TK; Lantero Rodriguez J; ; Snellman A; Suárez-Calvet M; Proitsi P; Zetterberg H; Blennow K
Alzheimers Res Ther; 2021 Jan; 13(1):17. PubMed ID: 33419453
[TBL] [Abstract][Full Text] [Related]
23. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
24. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy.
Chouliaras L; Thomas A; Malpetti M; Donaghy P; Kane J; Mak E; Savulich G; Prats-Sedano MA; Heslegrave AJ; Zetterberg H; Su L; Rowe JB; O'Brien JT
J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):651-658. PubMed ID: 35078917
[TBL] [Abstract][Full Text] [Related]
25. Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.
Han MR; Schellenberg GD; Wang LS;
BMC Neurol; 2010 Oct; 10():90. PubMed ID: 20932310
[TBL] [Abstract][Full Text] [Related]
26. Plasma biomarkers identify older adults at risk of Alzheimer's disease and related dementias in a real-world population-based cohort.
Ferreira PCL; Zhang Y; Snitz B; Chang CH; Bellaver B; Jacobsen E; Kamboh MI; Zetterberg H; Blennow K; Pascoal TA; Villemagne VL; Ganguli M; Karikari TK
Alzheimers Dement; 2023 Oct; 19(10):4507-4519. PubMed ID: 36876954
[TBL] [Abstract][Full Text] [Related]
27. Genetic architecture of plasma Alzheimer disease biomarkers.
Bradley J; Gorijala P; Schindler SE; Sung YJ; Ances B; ; Fernandez MV; Cruchaga C
Hum Mol Genet; 2023 Jul; 32(15):2532-2543. PubMed ID: 37208024
[TBL] [Abstract][Full Text] [Related]
28. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC
ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic value of isolated plasma biomarkers and its combination in neurodegenerative dementias: A multicenter cohort study.
Chen Y; Wang Y; Tao Q; Lu P; Meng F; Zhuang L; Qiao S; Zhang Y; Luo B; Liu Y; Peng G
Clin Chim Acta; 2024 May; 558():118784. PubMed ID: 38588788
[TBL] [Abstract][Full Text] [Related]
30. Associations of the APOE ε2 and ε4 alleles and polygenic profiles comprising APOE-TOMM40-APOC1 variants with Alzheimer's disease biomarkers.
Kulminski AM; Jain-Washburn E; Loiko E; Loika Y; Feng F; Culminskaya I;
Aging (Albany NY); 2022 Nov; 14(24):9782-9804. PubMed ID: 36399096
[TBL] [Abstract][Full Text] [Related]
31. Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population-based study.
Zhang Y; Ferreira PCL; Jacobsen E; Bellaver B; Pascoal TA; Snitz BE; Chang CH; Villemagne VL; Ganguli M; Karikari TK
Alzheimers Dement; 2024 Jun; 20(6):4199-4211. PubMed ID: 38753951
[TBL] [Abstract][Full Text] [Related]
32. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
33. Differential associations of clinical features with cerebrospinal fluid biomarkers in dementia with Lewy bodies and Alzheimer's disease.
de Oliveira FF; Miraldo MC; de Castro-Neto EF; de Almeida SS; Matas SLA; Bertolucci PHF; Naffah-Mazzacoratti MDG
Aging Clin Exp Res; 2023 Aug; 35(8):1741-1752. PubMed ID: 37264166
[TBL] [Abstract][Full Text] [Related]
34. Risk of Alzheimer's disease is associated with longitudinal changes in plasma biomarkers in the multi-ethnic Washington Heights-Hamilton Heights-Inwood Columbia Aging Project (WHICAP) cohort.
Gu Y; Honig LS; Kang MS; Bahl A; Sanchez D; Reyes-Dumeyer D; Manly JJ; Dage JL; Lantigua RA; Brickman AM; Vardarajan BN; Mayeux R
Alzheimers Dement; 2024 Mar; 20(3):1988-1999. PubMed ID: 38183363
[TBL] [Abstract][Full Text] [Related]
35. Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease.
Chatterjee P; Elmi M; Goozee K; Shah T; Sohrabi HR; Dias CB; Pedrini S; Shen K; Asih PR; Dave P; Taddei K; Vanderstichele H; Zetterberg H; Blennow K; Martins RN
J Alzheimers Dis; 2019; 71(3):775-783. PubMed ID: 31424403
[TBL] [Abstract][Full Text] [Related]
36. Associations of circulating C-reactive proteins, APOE ε4, and brain markers for Alzheimer's disease in healthy samples across the lifespan.
Wang Y; Grydeland H; Roe JM; Pan M; Magnussen F; Amlien IK; Watne LO; Idland AV; Bertram L; Gundersen TE; Pascual-Leone A; Cabello-Toscano M; Tormos JM; Bartres-Faz D; Drevon CA; Fjell AM; Walhovd KW
Brain Behav Immun; 2022 Feb; 100():243-253. PubMed ID: 34920091
[TBL] [Abstract][Full Text] [Related]
37. The heritability of blood-based biomarkers related to risk of Alzheimer's disease in a population-based sample of early old-age men.
Gillespie NA; Elman JA; McKenzie RE; Tu XM; Xian H; Reynolds CA; Panizzon MS; Lyons MJ; Eglit GML; Neale MC; Rissman RA; Franz C; Kremen WS
Alzheimers Dement; 2024 Jan; 20(1):356-365. PubMed ID: 37622539
[TBL] [Abstract][Full Text] [Related]
38. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
[TBL] [Abstract][Full Text] [Related]
39. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
[TBL] [Abstract][Full Text] [Related]
40. A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis.
West T; Kirmess KM; Meyer MR; Holubasch MS; Knapik SS; Hu Y; Contois JH; Jackson EN; Harpstrite SE; Bateman RJ; Holtzman DM; Verghese PB; Fogelman I; Braunstein JB; Yarasheski KE
Mol Neurodegener; 2021 May; 16(1):30. PubMed ID: 33933117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
